Si. Heiba et al., THE VALUE AND CORRELATES OF LEFT-VENTRICULAR CAVITY ASSESSMENT IN DIPYRIDAMOLE TL-201 SPET STUDIES, Nuclear medicine communications, 19(5), 1998, pp. 443-449
Left ventricular cavity (LVC) enlargement during SPET dipyridamole Tl-
201 myocardial perfusion imaging studies is a proven marker of severit
y of coronary artery disease. Nevertheless, the influence of the exten
t of myocardial infarct and ischaemia on the degree of LVC enlargement
both at rest and with dipyridamole has not been clearly analysed. One
hundred and one patients were studied by both dipyridamole myocardial
perfusion imaging and radionuclide ventriculography within 1 week. Th
e left ventricular ejection fraction (LVEF) was 57 +/- 9 in normal res
ting LVC patients (group I), 43 +/- 8 in mild LVC enlargement patients
(group II) and 28 +/- 5 in moderate-to-severe LVC enlargement patient
s (group III). The number of fixed defects was increased in patients i
n group II and group III, but there was no significant differences in
the number of ischaemic segments among groups. The number of ischaemic
segments was much higher in patients with transient cavity dilatation
than those without cavity change; nonetheless, both LVEF and the numb
ers of fixed segments were unchanged. The degree of LVC enlargement at
rest strongly reflects the resting left ventricular systolic function
as well as the extent of previous myocardial infarct. On the other ha
nd, transient cavity dilatation during dipyridamole infusion can only
reflect the extent of viable myocardium at risk. ((C) 1998 Lippincott-
Raven Publishers).